Literature DB >> 25332980

What is the role of vedolizumab in the era of anti-TNF agents?

Fong-Kuei F Cheng1, Leon P McLean1, Raymond K Cross1.   

Abstract

Entities:  

Year:  2014        PMID： 25332980      PMCID： PMC4200654          DOI： 10.3978/j.issn.2305-5839.2013.10.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

1.  In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1.

Authors:  K Matsuzaki; Y Tsuzuki; H Matsunaga; T Inoue; J Miyazaki; R Hokari; Y Okada; A Kawaguchi; S Nagao; K Itoh; S Matsumoto; S Miura
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 2.  Tissue-tropic effector T cells: generation and targeting opportunities.

Authors:  William W Agace
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

Review 3.  Review article: loss of response to anti-TNF treatments in Crohn's disease.

Authors:  S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2011-03-02       Impact factor: 8.171

4.  The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome.

Authors:  C Lahiff; P Safaie; A Awais; M Akbari; L Gashin; S Sheth; A Lembo; D Leffler; A C Moss; A S Cheifetz
Journal:  Aliment Pharmacol Ther       Date:  2013-02-21       Impact factor: 8.171

5.  Natalizumab induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-11-03       Impact factor: 91.245

Review 6.  Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Authors:  David Hunt; Gavin Giovannoni
Journal:  Pract Neurol       Date:  2012-02

7.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Albert Cohen; Alain Bitton; Jeffrey Baker; Réjean Dubé; Steven B Landau; Margaret K Vandervoort; Asit Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-01       Impact factor: 11.382

Review 8.  Review article: Crohn's disease: monitoring disease activity.

Authors:  R Sostegni; M Daperno; N Scaglione; A Lavagna; R Rocca; A Pera
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

9.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

10.  The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.

Authors:  Dulce Soler; Tobias Chapman; Li-Li Yang; Tim Wyant; Robert Egan; Eric R Fedyk
Journal:  J Pharmacol Exp Ther       Date:  2009-06-09       Impact factor: 4.030
View more
  1 in total

Review 1.  Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab.

Authors:  Jill Mv Petkau; Bertus Eksteen
Journal:  Biologics       Date:  2016-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.